A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI-H/DMMR METASTATIC COLORECTAL CANCER
Study of Pembrolizumab Alone or in Combination with Encorafenib and Cetuximab in Patients with Colon Cancer
Sponsor: Pfizer, Inc
Enrolling: Male and Female Patients
IRB Number: AAAU2336
U.S. Govt. ID: NCT05217446
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine if the study drugs, encorafenib, and cetuximab, taken in combination with pembrolizumab would improve compared to the outcome of pembrolizumab alone in study patients. Encorafenib and cetuximab target cancerous BRAF proteins and potentially slow down the growth of cancer cells. Pembrolizumab may help your immune system to kill cancer cells. Encorafenib is a BRAF inhibitor (a drug that can shrink or slow the growth of tumors) that is approved in several jurisdictions (including the United States US) in combination with cetuximab for the treatment of patients with metastatic BRAF mutant CRC, after prior therapy. Pembrolizumab is approved in the US for patients with mCRC with MSI-H/dMMR mutation that has not been treated.
Investigator
Gulam Manji, MD, PhD
Do You Qualify?
Are you at least 18 years old? Yes No
Are you able to swallow, retain, and absorb oral medications? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162